Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal intermediate chain 2 (DNAI2) is a structural protein encoded by the DNAI2 gene, forming a key intermediate chain within the axonemal dynein complex that powers the movement of motile cilia and flagella[1][3]. DNAI2 is essential for the assembly and function of outer dynein arms in respiratory cilia and sperm flagella, underlying its crucial roles in respiratory tract mucociliary clearance and fertility[1][3][5]. Mutations in DNAI2 cause an autosomal recessive disorder known as primary ciliary dyskinesia (CILD9), which manifests as lung disease, male infertility, and, more rarely, female subfertility due to defects in ciliary and flagellar motility[3][5][9]. Studies in mouse and other models support its involvement in both ciliary assembly and gametogenesis. DNAI2 may interact with signaling pathways such as STAT3, influencing tissue-specific proliferation and apoptosis, but it is not considered a classic pharmacological or therapeutic drug target[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein axonemal intermediate chain 2 (DNAI2).